Mydriasis Market, Size, Share, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Mydriasis Market, Size, Share, Trends, Epidemiology Forecast till 2030

September 11
20:15 2020
Mydriasis Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Mydriasis Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Mydriasis is the dilation of the pupil, which may be due to a non-physiological cause such as disease, trauma, drugs usage, or physiological pupillary response.

Currently, dilation is achieved by topical and/or intracameral administration of anticholinergic agents, sympathomimetic agents, or both, with the most commonly used being cyclopentolate, tropicamide, and phenylephrine. Topical mydriatic agents have been used for many years to dilate the pupil before cataract surgery. Moreover, ophthalmologists have been in search of new options to streamline the process of intraoperative mydriasis.

The approved therapies are the only current treatment available in the market of mydriasis, and there is a dearth of novel products in the pipeline. Furthermore, Omidria is going to generate the highest revenue, followed by topical regimen and intracameral Injections. Along with these approved therapies, the approval of Nyxol, a topical eye drop for the treatment of reversal of mydriasis in the future, can also contribute to the market in the forecast period. 

Mydriasis Market Insight

Mydriasis market size in 7MM in 2017 was USD 104.52 million  

Mydriasis Market Drivers

  • Rising Geriatric population
  • Cost-effectiveness of the Current Standard of Care

Mydriasis Market Barriers

  • Availability of Generic Options
  • Limited Research & Development

Request for sample pages

 

 

Scope of the Report

 

  • The report covers the descriptive overview of Mydriasis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Mydriasis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Mydriasis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Mydriasis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Mydriasis market

Table of contents

1. Key Insights

2. Executive Summary of Mydriasis

3. Competitive Intelligence Analysis for Mydriasis

4. Mydriasis: Market Overview at a Glance

4.1. Mydriasis Total Market Share (%) Distribution in 2017

4.2. Mydriasis Total Market Share (%) Distribution in 2030

5. Mydriasis: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Mydriasis Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Mydriasis Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Mydriasis Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Mydriasis Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Mydriasis Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Mydriasis Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Mydriasis Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Mydriasis Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Mydriasis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Mydriasis Treatment and Management

8.2. Mydriasis Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Mydriasis Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Mydriasis: Seven Major Market Analysis

13.1. Key Findings

13.2. Mydriasis Market Size in 7MM

13.3. Mydriasis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Mydriasis Total Market Size in the United States

15.1.2. Mydriasis Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Mydriasis Total Market Size in Germany

15.3.2. Mydriasis Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Mydriasis Total Market Size in France

15.4.2. Mydriasis Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Mydriasis Total Market Size in Italy

15.5.2. Mydriasis Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Mydriasis Total Market Size in Spain

15.6.2. Mydriasis Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Mydriasis Total Market Size in the United Kingdom

15.7.2. Mydriasis Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Mydriasis Total Market Size in Japan

15.8.3. Mydriasis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Mydriasis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Categories